These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27137860)

  • 1. [Not Available].
    Med Sci (Paris); 2016 Apr; 32 Spec No 1():34-9. PubMed ID: 27137860
    [No Abstract]   [Full Text] [Related]  

  • 2. Time to revisit the orphan drug law.
    Garattini S
    Eur J Clin Pharmacol; 2012 Feb; 68(2):113. PubMed ID: 21842335
    [No Abstract]   [Full Text] [Related]  

  • 3. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I; Breckenridge A
    Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orphan drugs revisited.
    McCabe C; Tsuchiya A; Claxton K; Raftery J
    QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
    [No Abstract]   [Full Text] [Related]  

  • 5. The Orphan Drug Act Revisited.
    Thomas S; Caplan A
    JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
    [No Abstract]   [Full Text] [Related]  

  • 6. Confusion over Article 8.
    Tambuyzer E
    EMBO Rep; 2005 Aug; 6(8):690. PubMed ID: 16065056
    [No Abstract]   [Full Text] [Related]  

  • 7. EU to review rare disease drugs market exclusivity.
    Sheridan C
    Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
    [No Abstract]   [Full Text] [Related]  

  • 8. Orphanage at the FDA.
    Chen E
    J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
    [No Abstract]   [Full Text] [Related]  

  • 9. Rare diseases: what's next?
    Remuzzi G; Garattini S
    Lancet; 2008 Jun; 371(9629):1978-9. PubMed ID: 18555899
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 11. [Towards targeted answers to emergency issues for rare diseases].
    Duguet C
    Med Sci (Paris); 2018 May; 34 Hors série n°1():16-18. PubMed ID: 29911547
    [No Abstract]   [Full Text] [Related]  

  • 12. Does orphan drug legislation really answer the needs of patients?
    Haffner ME; Torrent-Farnell J; Maher PD
    Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916
    [No Abstract]   [Full Text] [Related]  

  • 13. [Documentary research and self-instruction. Critical reading of a medical article. Practice guidelines. Part 1: rare diseases].
    Cordier JF; Aymé S
    Rev Prat; 2004 Apr; 54(7):777-9. PubMed ID: 15253297
    [No Abstract]   [Full Text] [Related]  

  • 14. Orphan drugs and orphan tests in the USA.
    Thoene JG
    Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
    [No Abstract]   [Full Text] [Related]  

  • 15. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing the use of orphan drugs in clinical practice.
    Hulton SA; Greener M
    Hosp Med; 2004 Jul; 65(7):400-3. PubMed ID: 15287343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Med Sci (Paris); 2016 Apr; 32 Spec No 1():29-33. PubMed ID: 27137859
    [No Abstract]   [Full Text] [Related]  

  • 18. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S
    Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
    [No Abstract]   [Full Text] [Related]  

  • 19. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. History of Orphan Drug Regulation-United States and Beyond.
    Haffner ME
    Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.